• Latest
  • Trending
  • All
  • Egypt
  • Business
  • Local
  • World
COVID rebound after Pfizer treatment likely due to robust immune response

COVID rebound after Pfizer treatment likely due to robust immune response

October 7, 2022
Türkiye, Qatar sign mutual defence agreement

Türkiye, Qatar sign mutual defence agreement

November 13, 2026
UN chief urges drastic emissions cuts

UN chief urges drastic emissions cuts

November 13, 2026
Egypt intelligence chief, Saddam Haftar discuss Libya political process

Egypt intelligence chief, Saddam Haftar discuss Libya political process

November 13, 2026
Blasts in Russia kill officer, hurt Ukrainian ex-PM adviser

Blasts in Russia kill officer, hurt Ukrainian ex-PM adviser

November 13, 2026
Spain’s Sanchez struggles to rally disillusioned left

Spain’s Sanchez struggles to rally disillusioned left

November 13, 2026
Russia: Europeans can join Ukraine peace talks

Russia: Europeans can join Ukraine peace talks

November 13, 2026
Israeli spy chief in Washington as Netanyahu presses Trump on Iran

Israeli spy chief in Washington as Netanyahu presses Trump on Iran

November 13, 2026
Raya Digital showcases integrated AI and automation solutions to drive enterprise performance

Raya Digital showcases integrated AI and automation solutions to drive enterprise performance

November 13, 2026
COP31

Egypt spotlights youth startups, green projects at COP31

November 13, 2026
Japan coach to leave job early after Asian Cup shift

Japan coach to leave job early after Asian Cup shift

November 13, 2026
  • Advertise
  • Privacy & Policy
  • Contact
Friday, November 13, 2026
  • Login

Editor-in-Chief

Mohamed Fahmy

Board Chairman

Tarek Lotfy

Egyptian Gazette
No Result
View All Result
  • HOME
  • EGYPT
    • Local
    • Features
  • World
    • National Day
  • Technology
  • BUSINESS
    • Real Estate
    • Automotive
  • SPORTS
  • ENTERTAINMENT
    • Arts
    • Health
    • Lifestyle
    • Travel
    • Tourism
    • Odd News
  • Skyward
    • Snippets from EgyptAir history
  • MORE
    • Multimedia
      • Video
      • Podcast
      • Gallery
    • OP-ED
  • HOME
  • EGYPT
    • Local
    • Features
  • World
    • National Day
  • Technology
  • BUSINESS
    • Real Estate
    • Automotive
  • SPORTS
  • ENTERTAINMENT
    • Arts
    • Health
    • Lifestyle
    • Travel
    • Tourism
    • Odd News
  • Skyward
    • Snippets from EgyptAir history
  • MORE
    • Multimedia
      • Video
      • Podcast
      • Gallery
    • OP-ED
No Result
View All Result
Egyptian Gazette
Home Entertainment Health

COVID rebound after Pfizer treatment likely due to robust immune response

by News Wires
October 7, 2022
in Health
A rebound of COVID-19 symptoms in some patients after taking Pfizer's antiviral Paxlovid may be related to a robust immune response rather than a weak one.

A rebound of COVID-19 symptoms in some patients after taking Pfizer's antiviral Paxlovid may be related to a robust immune response rather than a weak one.

Share on FacebookWhatsapp

CHICAGO – A rebound of COVID-19 symptoms in some patients after taking Pfizer’s antiviral Paxlovid may be related to a robust immune response rather than a weak one, US government researchers reported.

They concluded that taking a longer course of the drug – beyond the recommended five days – was not required to reduce the risk of a recurrence of symptoms as some have suggested, based on an intensive investigation of rebound in eight patients at the National Institutes of Health’s Clinical Center.

All patients in the study had developed robust immune responses, but researchers found higher levels of antibodies in the patients who experienced a rebound.

The team said their data argues against the hypothesis that impaired immune responses are the reason symptoms return in some patients.

“Our findings suggest that a more robust immune response rather than uncontrolled viral replication characterizes these clinical rebounds,” the team wrote according to Reuters.

The study, published in the journal Clinical Infectious Diseases, followed numerous reports of individuals who took Paxlovid as recommended within five days of infection and saw a return of symptoms after they completed the five-day course of treatment.

President Joe Biden and National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci both experienced a COVID rebound after taking the medicine.

The cases raised concerns that Pfizer’s two-drug antiviral treatment could interfere with development of a long-lasting immune response.

The study involved six people whose COVID symptoms returned after taking Paxlovid, and two with rebound symptoms after apparent recovery who did not take the pills.

Their responses were compared to a group of six people who had COVID but did not experience a rebound. All volunteers had been vaccinated and boosted and all were infected with some version of the Omicron variant of the virus.

Blood from study volunteers underwent intensive investigation to assess their immune response during the acute infection phase and the rebound phase.

All of the rebound patients had experienced significant improvement in their symptoms before their rebound. Of those who had a rebound after Paxlovid, four had milder symptoms than during their initial infection, one had the same level of severity and one reported worse symptoms.

None of the rebound patients required additional treatment or hospitalization.

Rebound symptoms may be partially driven by a robust immune response to residual virus in the respiratory tract, the study authors suggested. They concluded that the drug does not impede the immune response in some individuals, as some had feared.

Larger and more detailed studies are needed to further understand COVID symptom rebound, the research team said, adding that the current data supports the need for isolation of such patients.

The researchers also suggested that there is still a need to evaluate longer courses of Paxlovid in immunocompromised individuals where the immune response may be ineffective.

Tags: Covid-19HealthPaxlovidPfizerUSA

Discussion about this post

ADVERTISEMENT
egyptian-gazette-logo

The Egyptian Gazette is the oldest English-language daily newspaper in the Middle East.
It was first published on January 26, 1880 and it is part of El Tahrir Printing and Publishing House.

Follow Us

Türkiye, Qatar sign mutual defence agreement

UN chief urges drastic emissions cuts

Egypt intelligence chief, Saddam Haftar discuss Libya political process

Blasts in Russia kill officer, hurt Ukrainian ex-PM adviser

Spain’s Sanchez struggles to rally disillusioned left

  • Advertise
  • Privacy & Policy
  • Contact

Copyrights for © Egyptian Gazette - Administered by Digital Transformation Management.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • EGYPT
    • Local
    • Features
  • World
    • National Day
  • Technology
  • BUSINESS
    • Real Estate
    • Automotive
  • SPORTS
  • ENTERTAINMENT
    • Arts
    • Health
    • Lifestyle
    • Travel
    • Tourism
    • Odd News
  • Skyward
    • Snippets from EgyptAir history
  • MORE
    • Multimedia
      • Video
      • Podcast
      • Gallery
    • OP-ED

Copyrights for © Egyptian Gazette - Administered by Digital Transformation Management.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.